Glioblastoma (GBM) is a highly malignant type of primary brain tumor with a high mortality
rate. Although the current standard therapy consists of surgery followed by radiation and …

Chemotherapeutic drugs target a physiological differentiating feature of cancer cells as they
tend to actively proliferate more than normal cells. They have well-known side-effects …

Uncontrolled proliferation is the hallmark of cancer and other proliferative disorders and
abnormal cell cycle regulation is, therefore, common in these diseases. Cyclin-dependent …

Purvalanol A is a highly selective inhibitor of Cdc2 [also known as cyclin-dependent kinase
1 (CDK1)]. Taxol is an anti-tumor chemotherapeutic drug which is widely used clinically. In …

With the application of high throughput sequencing technologies at single-cell resolution,
studies of the tumor microenvironment in glioblastoma, one of the most aggressive and …

Abstract p28 is an anionic cell-penetrating peptide of 28 amino acids that activates wild-type
and mutated p53, leading subsequently to selective inhibition of CDK2 and cyclin A …

Cyclin-dependent kinases (CDKs) are important regulatory enzymes in the normal
physiological processes that drive cell-cycle transitions and regulate transcription. Virtually …

The alkylating agent, temozolomide (TMZ), is the most commonly used chemotherapeutic for
the treatment of glioblastoma (GBM). The anti-glioma effect of TMZ involves a complex …

Glioblastoma multiforme (GBM) is the most common primary brain tumor and is among the
deadliest of human cancers. Dysregulation of microRNAs (miRNAs) expression is an …

Despite extensive efforts and continual progress in research and medicine, outcomes for
patients with high-grade glioma remain exceptionally poor. Over the past decade, research …